LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Accueil・Liste d'Actions・Johnson and Johnson

Johnson and Johnson

Fermé

Secteur Soins de santé

164.37 -0.29

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

164.14

Max

164.71

Chiffres clés
By Trading Economics
Revenu	1.4B 4.7B
Ventes	1.1B 22B
P/E Moyenne du Secteur	21.72 103.001
BPA	2.82
Marge bénéficiaire	20.873
Employés	131,900
EBITDA	2.1B 7.8B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+4.92 upside

Dividendes
By Dow Jones
Prochains Résultats	15 oct. 2024
Date du Prochain Dividende	10 sept. 2024
Date du Prochain Détachement de Dividende	18 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	400B
Ouverture précédente	164.66
Clôture précédente	164.37

Sentiment de l'Actualité

By Acuity

55%

45%

293 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

164.13 / 164.61 Support & Résistance

Johnson and Johnson Graphique

Actualités Associées

20 août 2024, 12:16 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600 Million

20 août 2024, 11:43 UTC

Actualités

Johnson & Johnson's Rybrevant, Lazcluze Combo Gets FDA Approval for Type of Advanced Lung Cancer

17 juil. 2024, 14:14 UTC

Résultats

Trending: Johnson & Johnson Beats 2Q Sales Guidance

4 sept. 2024, 23:20 UTC

Actualités

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

23 août 2024, 20:54 UTC

Actualités

J&J Takes Aim at Hospital Drug-Discount Program -- Update

23 août 2024, 18:09 UTC

Actualités

J&J Takes Aim At Hospital Drug-Discount Program -- WSJ

20 août 2024, 12:41 UTC

Actualités

Acquisitions, Fusions, Rachats

Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion -- Barrons.com

20 août 2024, 12:01 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600M

20 août 2024, 11:55 UTC

Acquisitions, Fusions, Rachats

J&J To Acquire V-Wave For Up To $1.7 Billion In Play For Heart Failure Device -- MarketWatch

20 août 2024, 11:31 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Expects the Transaction to Dilute Adjusted EPS by 24c in 2024 and 6c in 2025 >JNJ

20 août 2024, 11:31 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Transaction Is Expected to Close Before the End of 2024 >JNJ

20 août 2024, 11:31 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Will Join Johnson & Johnson as Part of Johnson & Johnson MedTech >JNJ

20 août 2024, 11:31 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Will Acquire V-Wave for an Upfront Payment of $600M With the Potential for Additional Regulatory and Comml Milestone Payments Up to $1.1B >JNJ

20 août 2024, 11:30 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson To Acquire V-Wave >JNJ

20 août 2024, 11:12 UTC

Actualités

Johnson & Johnson Wins First FDA Approval For Chemotherapy-Free Lung Cancer Treatment -- MarketWatch

12 août 2024, 14:30 UTC

Acquisitions, Fusions, Rachats

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 août 2024, 09:30 UTC

Actualités

Acquisitions, Fusions, Rachats

Big Drugmakers Are Clinching Smaller Deals -- WSJ

29 juil. 2024, 10:30 UTC

Actualités

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

17 juil. 2024, 11:24 UTC

Market Talk

Résultats

Acquisitions, Fusions, Rachats

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17 juil. 2024, 10:43 UTC

Résultats

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson: 2Q Innovative Medicine Worldwide Operational Sales, Excluding Covid Vaccine, Grew 8.8% >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson Updating 2024 Guidance to Reflect Improved Performance and Impact for Recent Acquisitions of Shockwave Medical, Proteologix and NM26 Bispecific Antibody >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson Raises 2024 Operational Sales View to $89.2B-$89.6B Vs Prior View $88.7B-$89.1B >JNJ

17 juil. 2024, 10:20 UTC

Résultats

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

Comparaison

Variation de prix

Johnson and Johnson prévision

Objectif de Prix

By TipRanks

4.92% hausse

Prévisions sur 12 Mois

Moyen 172.46 USD 4.92%

Haut 215 USD

Bas 150 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

164.13 / 164.61Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

293 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.